Coagulation factor V: A plethora of anticoagulant molecules

Current Opinion in Hematology

Volumn 12, Issue 2, 2005, Pages 141-148

  Kalafatis, Michael ^a,b  

^a CLEVELAND STATE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulant; Factor V; Factor Xa; Phospholipid; Prothrombin; Prothrombinase; Thrombin; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; PROTHROMBIN; THROMBIN;

BINDING SITE; BLEEDING; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; ELECTRICITY; HEAVY CHAIN; HEMOSTASIS; HUMAN; HYDROPHOBICITY; LIGHT CHAIN; MEMBRANE BINDING; MOLECULAR INTERACTION; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ANIMALS; BINDING SITES; BLOOD COAGULATION; FACTOR V; FACTOR XA; HUMANS; THROMBOPLASTIN;

EID: 14644388217     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000155016.30296.90     Document Type: Review

References (86)

1. Kalafatis M, Egan JO, van't Veer C, et al. The regulation of clotting factors. Crit Rev Eukaryot Gene Expr 1997; 7:241-280. A comprehensive review of the various mechanisms involved in the initiation and propagation of blood coagulation.
2. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003; 101:20-30. A comprehensive review of the role of factor V during coagulation. It correlates structural abnormalities within the factor V molecule to physiological phenomena in patients with bleeding and/or thrombotic episodes.
3. Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979; 254:10952-10962.
4. Rosing J, Tans G, Govers-Riemslag, et al. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1979; 255:274-283.
5. Nesheim ME, Mann KG. The kinetics and cofactor dependence of the two cleavages involved in prothrombin activation. J Biol Chem 1983; 258:5386-5391.
6. Krishnaswamy S, Church WR, Nesheim ME, Mann KG. Activation of human prothrombin by human prothrombinase: Influence of factor Va on the reaction mechanism. J Biol Chem 1987; 262:3291-3299.
7. Rosing J, Zwaal RF, Tans G. Formation of meizothrombin as intermediate in factor Xa-catalyzed prothrombin activation. J Biol Chem 1986; 261:4224-4228.
8. Krishnaswamy S, Mann KG, Nesheim ME. The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction. J Biol Chem 1986; 261:8977-8984.
9. Krishnaswamy S. Prothrombinase complex assembly. Contributions of protein-protein and protein-membrane interactions toward complex formation. J Biol Chem 1990; 265:3708-3718.
10. Krishnaswamy S, Jones KC, Mann KG. Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 1988; 263:3823-3834.
11. Esmon CT. The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem 1979; 254:964-973.
12. Suzuki K, Dahlbäck B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982; 257:6556-6564.
13. Kane WH, Majerus PW. Purification and characterization of human coagulation factor V. J Biol Chem 1981; 256:1002-1007.
14. Kalafatis M, Mann KG. Role of the membrane in the inactivation of factor Va by activated protein C. J Biol Chem 1993; 268:27246-27257.
15. 306 of the heavy chain is required for inactivation.
16. Nicolaes GAF, Tans G, Thomassen MCLGD, et al. Peptide bond cleavages and loss of functional acticity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270:21158-21166.
17. Mann KG, Hockin MF, Begin KJ, Kalafatis M. Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem 1997; 272:20678-20683. The first demonstration that factor Va inactivation by APC results in the release of the A2 domain.
18. Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31:3777-3785. First determination of the entire factor V gene.
19. Jenny RJ, Pittman DD, Toole JJ, et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA 1987; 84:4846-4850.
20. Kane WH, Ichinose A, Hagen FS, Davie EW. Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats. Biochemistry 1987; 26:6508-6514.
21. Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71:539-555.
22. Tracy PB, Eide LL, Bowie EJW, Mann KG. Radioimmunoassay of factor V in Human Plasma and Platelets. Blood 1982; 60:59-63.
23. Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998; 92:3035-3041.
24. Gould WR, Silveira JR, Tracy PB. Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor Va. J Biol Chem 2004; 279:2383-2393.
25. Yang TL, Pipe SW, Yang A, et al. Biosynthetic origin and functional significance of murine platelet factor V. Blood 2003;102:2851-2855.
26. Sun H, Yang TL, Yang A, et al. The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. Blood 2003; 102:2856-2861.
27. Hayward CP, Warketin TE, Horsewood P, Kelton JG. Multimerin: a series of large disulfide-linked multimeric proteins within platelets. Blood 1991; 77:2556-2560. Initial identification of multimerin, the carrier protein for factor V in platelets.
28. Hayward CP, Bainton DF, Smith JW, et al. Multimerin is found in the alpha-granules of resting platelets and is synthesized by a megakaryocytic cell line. J Clin Invest 1993; 91:2630-2639.
29. Hayward CP, Furmaniak-Kazmierczack E, Cieutat AM, et al. Factor V is complexed with multimerin in resting platelet lysates and colocalizes with multimerin in platelet alpha-granules. J Biol Chem 1995; 270:19217-19224.
30. Hayward CP, Hassel JA, Denomme GA, et al. The cDNA sequence of human endothelial cell multimerin. A unique protein with RGDS, coiled-coil, and epidermal growth factor-like domains and a carboxyl terminus similar to the globular domain of complement C1q and collages type VIII and X. J Biol Chem 1995; 270:18246-18251.
31. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989; 73:185-190.
32. Omar MN, Mann KG. Inactivation of factor Va by plasmin. J Biol Chem 1987; 15:9750-9755.
33. Kalafatis M, Mann KG. The role of the membrane in the inactivation of factor Va by plasmin. Amino acid region 307-348 of factor V plays a critical role for factor Va cofactor function. J Biol Chem 2001; 276:18614-18623.
34. Zeibdawi AR, Pryzdial EL. Mechanism of factor Va inactivation by plasmin. Loss of A2 and A3 domains from a Ca2+-dependent complex of fragments bound to phospholipid. J Biol Chem 2001; 276:19929-19936.
35. Krishnaswamy S, Russel GD, Mann KG. The reassociation of factor Va from its isolated subunits. J Biol Chem 1989; 264:3160-3168.
36. Adams TE, Hockin MF, Mann KG, Everse SJ. The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function. Proc Natl Acad Sci USA 2004; 101:8918-8923. The first report of a partial crystal structure of coagulation factor Va. It gives new insights on chain-chain association as well as on the orientation of the lipid binding domains located at the carboxyl-terminus of the light chain.
37. Hortin GL. Sulfation of tyrosine residues in coagulation factor V. Blood 1993; 76:946-952.
38. Pittman DD, Tomkinson KN, Michnick D, et al. Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity. Biochemistry 1994; 33:6952-6959.
39. Pittman DD, Tomkinson KN, Kaufman RJ. Post-translational requirement for functional factor V and factor VIII secretion in mammalian cells. J Biol Chem 1994; 269:17329-17337.
40. Kalafatis M, Rand MD, Jenny RJ, et al. Phosphorylation of factor Va and factor VIIIa by activated platelets. Blood 1993; 81:704-719.
41. Rand MD, Kalafatis M, Mann KG. Platelet coagulation factor Va: the major secretory platelet phosphoprotein. Blood 1994; 83:2180-2190.
42. Kalafatis M. Identification and partial characterization of factor Va heavy chain-kinase from human platelets. J Biol Chem 1998; 273:8459-8466.
43. Guinto ER, Esmon CT, Mann KG, MacGillivray RT. The complete cDNA sequence of bovine coagulation factor V. J Biol Chem 1992; 267:2971-2978.
44. Yang TL, Cui J, Rehumtulla A, et al. The structure and function of murine factor V and its inactivation by protein C. Blood 1998; 91:4593-4599.
45. Grimm DR, Colter MB, Braunschweig M, et al. Porcine factor V: cDNA cloning, gene mapping, three-dimensional protein modeling of membrane binding sites and comparative anatomy of domains. Cell Mol Life Sci 2001; 58:148-159.
46. Singh LS, Kalafatis M. Sequencing of full length cDNA encoding the α and β subunits of human casein kinase II from human platelets and megakaryocytic cells. Expression of casein kinase IIα intronless gene in a megakaryocytic cell line. Biochemistry 2002; 41:8935-8940.
47. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90:1004-1008. Initial identification of a defect in the factor V molecule making it 'resistance to APC'.
48. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67. Initial identification of the mutation inducing 'resistance to APC' at the DNA level. This mutation is the most common mutation associated with a disease state (thrombotic tendency).
49. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342:1503-1506.
50. 506 of factor V. Lancet 1994; 343:1535-1536.
51. R506Q. J Biol Chem 1995; 270:4053-4057. Initial identification of the molecular mechanism inducing 'APC resistance' in patients homozygous for the defect.
52. R506Q by activated protein C. J Biol Chem 1995; 270:27852-27858.
53. Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85:3405-3411.
54. Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance. Biochem J 1996;313:467-472.
55. Kalafatis M, Xue J, Lawler CM, Mann KG. Contribution of the heavy and light chains of factor Va to the interaction with factor Xa. Biochemistry 1994; 33:6538-6545.
56. Heeb MJ, Kojima Y, Hackeng TM, Griffin JH. Binding sites for blood coagulation factor Xa and protein S involving residues 493-506 in factor Va. Protein Sci 1996; 5:1883-1889.
57. Kalafatis M, Beck DO. Identification of a binding site for blood coagulation factor Xa on the heavy chain of factor Va. Amino acid residues 323-331 of factor V represent an interactive site for activated factor X. Biochemistry 2002; 41:12715-12728.
58. Singh LS, Bukys MA, Beck DO, Kalafatis M. Amino acids Glu323, Tyr324, Glu330, and Val331 of factor Va heavy chain are essential for expression of cofactor activity. J Biol Chem 2003; 278:28335-28345.
59. Rezaie AR. Exosite-dependent regulation of the protein C anticoagulant pathway. Trends Cardiovasc Med 2003; 13:8-15.
60. Guillin MC, Bezeaud A, Bouton MC, Jandrot-Perrus M. Thrombin specificity. Thromb Haemost 1995; 74:129-133.
61. Rydel TJ, Ravichandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 1990; 249:277-280.
62. Bode W, Stubbs MT. Spatial structure of thrombin as a guide to its multiple sites of interaction. Semin Thromb Hemost 1993; 19:321-333.
63. Guinto ER, Esmon CT. Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. J Biol Chem 1984; 259:13986-13992.
64. Luckow EA, Lyons DA, Ridgeway TM, et al. Interaction of clotting factor V heavy chain with prothrombin and prethrombin 1 and role of activated protein C in regulating this interaction: analysis by analytical ultracentrifugation. Biochemistry 1989; 28:2348-2354.
65. Anderson PJ, Nesset A, Dharmawardana KR, Bock PE. Role of proexosite I in factor Va-dependent substrate interactions of prothrombin activation. J Biol Chem 2000; 275:16435-16442.
66. Dharmawardana KR, Olson ST, Bock PE. Role of regulatory exosite I in binding of thrombin to human factor V, factor Va, factor Va subunits, and activation fragments. J Biol Chem 1999; 274:18635-18643.
67. Dharmawardana KR, Bock PE. Demonstration of exosite I-dependent interactions of thrombin with human factor V and factor Va involving the factor Va heavy chain: analysis by affinity chromatography employing a novel method for active-site-selective immobilization of serine proteinases. Biochemistry 1998; 37:13143-13152.
68. Chen L, Yang L, Rezaie AR. Proexosite-1 on prothrombin is a factor Va-dependent recognition site for the prothrombinase complex. J Biol Chem 2003; 278:27564-27569.
69. Bakker HM, Tans G, Thomassen MC, et al. Functional properties of human factor Va lacking the Asp683-Arg709 domain of the heavy chain. J Biol Chem 1994; 269:20662-20667.
70. Camire RM, Kalafatis M, Tracy PB. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding. Biochemistry 1998; 37:11896-11906.
71. Kalafatis M, Beck DO, Mann KG. Structural requirements for expression of factor Va activity. J Biol Chem 2003; 278:33550-33561.
72. Beck DO, Bukys MA, Singh LS, et al. The contribution of amino acid region ASP695-TYR698 of factor V to procofactor activation and factor Va function. J Biol Chem 2004; 279:3084-3095.
73. Krishnaswamy S, Mann KG. The binding of factor Va to phospholipid vesicles. J Biol Chem 1988; 263:5714-5723.
74. Kalafatis M, Jenny RJ, Mann KG. Identification and characterization of a phospholipid-binding site of bovine factor Va. J Biol Chem 1990; 265:21580-21589.
75. Kalafatis M, Rand MD, Mann KG. Factor Va-membrane interaction is mediated by two regions located on the light chain of the cofactor. Biochemistry 1994; 33:486-493.
76. Lecompte MF, Bouix G, Mann KG. Electrostatic and hydrophobic interactions are involved in factor Va binding to membranes containing acidic phospholipid. J Biol Chem 1994; 269:1905-1910.
77. Saleh M, Peng W, Quinn-Allen MA, et al. The factor V C1 domain is involved in membrane binding: identification of functionally important amino acid residues within the C1 domain of factor V using alanine scanning mutagenesis. Thromb Haemost 2004; 91:16-27.
78. Peng W, Quinn-Allen MA, Kim SW, et al. Trp2063 and Trp2064 in the factor Va C2 domain are required for high-affinity binding to phospholipid membranes but not for assembly of the prothrombinase complex. Biochemistry 2004; 43:4385-4393.
79. Kim SW, Quin-Allen MA, Camp JT, et al. Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scsnning mutagenesis. Biochemistry 2000; 39:1951-1958.
80. Spiegel PC, Kaiser SM, Simon JA, Stoddard BL. Disruption of protein-membrane binding and identification of small-molecule inhibitors of coagulation factor VIII. Chem Biol 2004; 11:1413-1422.
81. Cui J, O'Shea KS, Purkayastha A, et al. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 1996; 384:66-68.
82. Montefuso MC, Duga S, Asselta R, et al. A novel two base pair deletion in the factor V gene associated with severe factor V deficiency. Br J Hematol 2000; 111:1240-1246.
83. Guash JF, Cannegieter S, Reitsma PH, et al. Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Hematol 1998; 101:32-39.
84. 221-to-Val substitution results in reduced cofactor activity. Blood 1995; 86:1820-1827.
85. R506Q mutation. Blood 1996; 88:1183-1187.
86. 10400→T) and heterozygous factor V Leiden. Haemophilia 2001; 7:511-514.